Entering text into the input field will update the search result below

Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q2 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET

Company Participants

Andrea Flynn – Investor Relations

Bruce Cozadd – Chairman and Chief Executive Officer

Renee Gala – Executive Vice President and Chief Financial Officer

Dan Swisher – President

Rob Iannone – Executive Vice President-R&D and Chief Medical Officer

Conference Call Participants

Ken Cacciatore – Cowen and Company

Jessica Fye – JPMorgan

Jason Gerberry – Bank of America

Melina Santoro – Morgan Stanley

David Amsellem – Piper Sandler

Gary Nachman – BMO Capital Markets

Annabel Samimy – Stifel

Esther Rajavelu – UBS

Marc Goodman – SVB Leerink

Graig Suvannavejh – Goldman Sachs

David Steinberg – Jefferies

Balaji Prasad – Barclays


Good day and thank you for standing-by. Welcome to the Second Quarter 2021 Jazz Pharmaceuticals Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Andrea Flynn. Please go ahead.

Andrea Flynn

Thank you and good afternoon, everyone. Today Jazz Pharmaceuticals reported its second quarter 2021 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.

On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, Executive Vice President and Chief Financial Officer; Dan Swisher, President; and Rob Iannone; Executive Vice President, R&D and Chief Medical Officer; Phil Jochelson, Neuroscience Therapeutic Head will also join the team for Q&A.

On Slide 2, I’d like to remind you that today’s webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated development and commercialization milestones and goals, which involve risks and uncertainties

Recommended For You

Comments (1)

Bruce Cozadd (CEO) sold 1750 shares the day before this call. WTF? Is this even allowed with insider trading laws? Shouldn't there be a blackout period? I guess he thought the call wouldn't go well.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.